Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
TRENDS
As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
By Reiji Anasako With Takeda Pharmaceutical’s global R&D transformation making steady headway, the launch of its drug discovery joint venture, Scohia Pharma, announced on March 14 provided the industry with a clearer picture of what the company’s new Japan R&D…
To read the full story
Related Article
- Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
- INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
TRENDS
- Top 10 PHARMA JAPAN Articles of 2025
December 23, 2025
- Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…